

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Adding pertuzumab to adjuvant chemotherapy/trastuzumab in the Phase III APHINITY study reduced the relative risk of recurrence by about 20% for patients with node-positive or high-risk node-negative, HER2-positive early BC.
 - a. True
 - b. False
2. Results of the APT trial evaluating adjuvant paclitaxel/trastuzumab for node-negative, HER2-positive BC showed that the rate of distant recurrence after a 7-year follow-up analysis was approximately _____.
 - a. 1%
 - b. 15%
 - c. 50%
3. The Phase III CREATE-X trial demonstrated that the addition of adjuvant capecitabine after standard neoadjuvant chemotherapy elicited a benefit in terms of overall survival among patients with _____ BC and residual invasive disease.
 - a. HER2-positive
 - b. HER2-negative
4. Which of the following groups derived a significant benefit from neratinib in the Phase III ExteNET study, which randomly assigned patients who received 1 year of adjuvant trastuzumab-based therapy to neratinib treatment or no further treatment?
 - a. All patients with HER2-positive BC
 - b. Patients with ER-positive, HER2-positive BC
 - c. Patients with ER-negative, HER2-positive BC
5. The Phase III OlympiAD trial of olaparib monotherapy versus physician's choice of chemotherapy for patients with HER2-negative mBC and a germline BRCA mutation demonstrated a statistically significant improvement in progression-free survival with olaparib.
 - a. True
 - b. False
6. In terms of treatment side effects, patients receiving abemaciclib may exhibit _____ neutropenia and _____ diarrhea compared to those undergoing treatment with palbociclib and ribociclib.
 - a. Less, more
 - b. Similar, similar
 - c. Similar, more
 - d. More, less
7. Treatment with which of the following CDK4/6 inhibitors requires patients to undergo EKG and liver function test monitoring?
 - a. Abemaciclib
 - b. Palbociclib
 - c. Ribociclib
 - d. All of the above
8. The CNS objective response rate for patients with HER2-positive BC brain metastases is increased approximately 5-fold for those who receive neratinib and capecitabine compared to neratinib alone.
 - a. True
 - b. False
9. In the OlympiAD trial for patients with HER2-negative, germline BRCA mutation-positive mBC, which of the following chemotherapies was not allowed as physician's choice for comparison to olaparib?
 - a. Capecitabine
 - b. Vinorelbine
 - c. Gemcitabine
 - d. Carboplatin
10. At ESMO 2017, Cottu and colleagues presented a Phase II study demonstrating _____ activity with neoadjuvant letrozole and palbociclib versus chemotherapy for patients with luminal BC.
 - a. Inferior
 - b. Comparable
 - c. Superior